



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

November 29, 2016

Corporate Relationship Department
M/s. BSE Ltd
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra–Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Sub: Press Release

Please find enclose herewith the Press Release for your information.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

For 
M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/12/2016

Press Release

NATCO RECEIVES FINAL APPROVAL FOR GENERIC ARMODAFINIL TABLETS for USA market


Hyderabad, India, November 29th, 2016

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce final approval of Abbreviated New Drug Application (ANDA) containing a paragraph IV certification filed with the U.S. Food and Drug Administration (FDA) for generic version of Armodafinil Tablets, 50 mg, 150 mg, and 250 mg. NATCO and its marketing partner Breckenridge Pharmaceutical, Inc., plan to launch this product in the USA market immediately.

Cephalon (acquired by Teva in 2011) sells Armodafinil 50mg, 150mg, and 250mg Tablets under Brand name NUVUGIL® in the USA market. NUVUGIL® is a wakefulness promoting agent for oral administration. NUVUGIL® Tablets had U.S. sales of approximately \$480 Million for twelve months ending December 2015, according to IMS Health.

Forwarded for favor of publication

For NATCO Pharma Limited


Rajeev Nannapaneni
Vice Chairman & CEO